Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

NCT02760433 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
368
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

R-Pharm International, LLC

Collaborators